Neurological Surgery 脳神経外科51巻4号

2023年07月発行

特集 下垂体腫瘍診療の新フェーズ—変革期の疫学・診断・治療における必須知識 Ⅱ 下垂体腫瘍の疫学・遺伝・病態

下垂体腫瘍の分子病理学的メカニズム

著者： 植田良¹ 戸田正博¹

所属機関： ¹慶應義塾大学医学部脳神経外科

ページ範囲：P.615 - P.623

Point
・下垂体腫瘍における分子病理学的メカニズムが解明され，その病理分類は組織学的分類から分子遺伝学的分類にシフトしている．
・下垂体腫瘍治療においても，個々の分子生物学的特徴に基づき薬物治療や集学的治療を行う個別化医療の可能性が示されつつある．
・新たな腫瘍分類の提唱，治療開発がまさに進行しており，脳神経外科医も最新の分子病理学的知識に精通することが求められている．

参考文献

1）Mizokami Y, et al：Expression of MSX1 in human normal pituitaries and pituitary adenomas. Endocr Pathol 19：54-61, 2008

2）Kontogeorgos G：Update on pituitary adenomas in the 2017 World Health Organization classification：innovations and perspectives. Hormones（Athens）20：287-291, 2021

3）Miyai S, et al：Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line. Cell Tissue Res 322：269-277, 2005

4）Zafar M, et al：Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 80：3621-3627, 1995

5）Sanno N, et al：Expression of Pit-1 and estrogen receptor messenger RNA in prolactin-producing pituitary adenomas. Mod Pathol 9：526-533, 1996

6）Dasen JS, et al：Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. Cell 97：587-598, 1999

7）Umeoka K, at al：Expression of GATA-2 in human pituitary adenomas. Mod Pathol 15：11-17, 2002

8）Aylwin SJ, et al：The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab 86：2476-2483, 2001

9）Lamolet B, et al：A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104：849-859, 2001

10）Srirangam Nadhamuni V, Korbonits M：Novel insights into pituitary tumorigenesis：genetic and epigenetic mechanisms. Endocr Rev 41：821-846, 2020

11）Tanaka C, et al：Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN1 gene in sporadic pituitary adenomas. J Clin Endocrinol Metab 83：2631-2634, 1998

12）Stergiopoulos SG, et al：Pituitary pathology in Carney complex patients. Pituitary 7：73-82, 2004

13）Solarski M, et al：DICER1 gene mutations in endocrine tumors. Endocr Relat Cancer 25：R197-R208, 2018　doi：10.1530/ERC-17-0509

14）Asa SL, Ezzat S：Genetics and proteomics of pituitary tumors. Endocrine 28：43-47, 2005

15）Kageyama K, et al：Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation. Endocr J 67：177-184, 2020

16）Ezzat S：Epigenetic control in pituitary tumors. Endocr J 55：951-957, 2008

17）Qian ZR, et al：Tumor-specific downregulation and methylation of the CDH13（H-cadherin）and CDH1（E-cadherin）genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20：1269-1277, 2007

18）Yuan Y, et al：Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. Mod Pathol 21：856-865, 2008

19）Qian ZR, et al：Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85：464-473, 2005

20）Qian ZR, et al：Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 22：431-441, 2009

21）Uroda T, et al：Conserved pseudoknots in lncRNA MEG3 are essential for stimulation of the p53 pathway. Mol Cell 75：982-995. e9, 2019　doi：10.1016/j.molcel.2019.07.025

22）Raverot G, et al：Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17：671-684, 2021

23）Liu W, et al：Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci 12：791-794, 2005

24）Yoshida D, et al：Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs（RECK）. J Neurooncol 89：141-150, 2008

25）Marques P, et al：The microenvironment of pituitary adenomas：biological, clinical and therapeutical implications. Pituitary 25：363-382, 2022

26）Acebrón A, et al：Congenital human thyroglobulin defect due to low expression of the thyroid-specific transcription factor TTF-1. J Clin Invest 96：781-785, 1995

27）Preda V, et al：The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis. Endocr Pathol 26：1-8, 2015　doi：10.1007/s12022-014-9341-8

28）Donson AM, et al；Advancing Treatment for Pediatric Craniopharyngioma Consortium：Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol 76：779-788, 2017

29）Dorris K：Tocilizumab in children with ACP. 2021 ClinicalTrials.gov Identifier：NCT03970226.　https://clinicaltrials.gov/ct2/show/NCT03970226（2023年3月13日アクセス）

30）Hölsken A, et al：EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res 17：4367-4377, 2011

31）Brastianos P, et al：Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst 108：djv310, 2015　doi：10.1093/jnci/djv310